Indolent Presentations of Leukemic Lung Disease in Acute Myeloid Leukemia
Authors:
- Yukiko KunitomoYKYukiko Kunitomo
- Seohyuk LeeSLSeohyuk Lee
- Chace C. AveryCAChace C. Avery
- Patricia L. Valda ToroPTPatricia L. Valda Toro
- Avi J. CohenACAvi J. Cohen
- Solmaz Ehtashimi-AfsharSESolmaz Ehtashimi-Afshar
- Peter A. KahnPKPeter A. Kahn
- Alexa SiddonASAlexa Siddon
- Prajwal BodduPBPrajwal Boddu
- Rupak DattaRDRupak Datta
- Charles S. Dela CruzCCCharles S. Dela Cruz
- Samir GautamSGSamir Gautam
Preprint
- 14 October 2020
- preprint
- Published by Cold Spring Harbor Laboratory in medRxiv
Abstract
Background: Patients with active acute myelogenous leukemia (AML) are at risk for leukemic infiltration (LI) into the lung and acute tumor lysis pneumopathy (ATLP) following chemotherapy. Fulminant presentations of these leukemic lung diseases are well-described, but indolent forms have not yet been studied. Therefore, we sought to elucidate the clinical features of mild-to-moderate LI and ATLP.Methods: A retrospective cohort analysis was performed on 51 hospitalized patients with AML, circulating blast count ≥3%, non-critical illness, and receipt of bronchoscopy between 2015-2019. Diagnoses of LI and ATLP were made via retrospective chart review by a multidisciplinary team of physicians.Results: 19 cases of leukemic lung disease were identified: 14 with LI and 5 with ATLP. The clinical presentations closely resembled pneumonia, with the majority demonstrating respiratory symptoms (63%), hypoxemia (63%), fever (84%), and pulmonary opacities (100%). All patients were presumptively diagnosed with infection, leading to an average of 18 days of broad-spectrum antibiotic therapy and multiple instances of delayed chemotherapy in treatment candidates. Although most patients were near the end-of-life (90% died within 1 year), transitions to comfort care were infrequent (25%) and hospitalizations were protracted (median 25 days).Conclusions: LI and ATLP are common yet under-recognized pulmonary complications in patients with active AML. When presenting indolently, these conditions are difficult to distinguish from lung infection, leading to missed diagnosis, inappropriate antibiosis, chemotherapy deferrals, and prolonged hospitalizations. Greater awareness and consensus definitions of LI and ATLP are therefore needed to improve care of this population.Keywords
This publication has 44 references indexed in Scilit:
- Acute respiratory failure in immunocompromised adultsThe Lancet Respiratory Medicine, 2019
- Acute Respiratory Failure in Patients with Hematologic MalignanciesClinics in Chest Medicine, 2017
- Respiratory events at the earliest phase of acute myeloid leukemiaLeukemia & Lymphoma, 2014
- Pneumonia during Remission Induction Chemotherapy in Patients with Acute LeukemiaAnnals of the American Thoracic Society, 2013
- Disease biology rather than age is the most important determinant of survival of patients ≥ 60 years with acute myeloid leukemia treated with uniform intensive therapyCancer, 2005
- The Prognosis of Acute Respiratory Failure in Critically Ill Cancer PatientsMedicine, 2004
- Incidence and prognostic value of respiratory events in acute leukemiaLeukemia, 2004
- Pneumonia in Acute Leukemia Patients During Induction Therapy: Experience in a Single InstitutionLeukemia & Lymphoma, 2003
- Pulmonary complications in patients with haematological malignancies treated at a respiratory ICUEuropean Respiratory Journal, 1998
- Pulmonary Complications of LeukemiaChest, 1990